2018
Cast of the Right Bronchial Tree
Woodard GA, Wieselthaler GM. Cast of the Right Bronchial Tree. New England Journal Of Medicine 2018, 379: 2151-2151. PMID: 30485771, DOI: 10.1056/nejmicm1806493.Peer-Reviewed Original Research
2016
Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity
Woodard GA, Crockard JC, Clary‐Macy C, Zoon‐Besselink C, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity. Journal Of Surgical Oncology 2016, 114: 838-847. PMID: 27569043, DOI: 10.1002/jso.24409.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinomaChemoradiotherapy, AdjuvantEsophageal NeoplasmsEsophagectomyFemaleFollow-Up StudiesHumansLaparoscopyMaleMiddle AgedMinimally Invasive Surgical ProceduresNeoadjuvant TherapyNeoplasm Recurrence, LocalNeuroendocrine TumorsPostoperative ComplicationsProspective StudiesSurvival AnalysisThoracotomyTreatment OutcomeConceptsNeoadjuvant chemoradiationEsophagectomy approachesLong-term overall survival rateInvasive Ivor Lewis esophagectomyLow perioperative morbidityPostoperative complication rateClear survival benefitFive-year survivalIvor Lewis esophagectomyMajority of patientsOverall survival rateEsophageal cancer patientsInvasive esophagectomy (MIE) approachPatients 58Hospital stayNeoadjuvant treatmentPerioperative complicationsPerioperative morbidityPostoperative complicationsProspective databaseClinical characteristicsOverall survivalSurvival benefitComplication rateMajor complicationsSignificance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics
Yang D, Woodard G, Zhou C, Wang X, Liu Z, Ye Z, Li K. Significance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics. Thoracic Cancer 2016, 7: 535-542. PMID: 27766777, PMCID: PMC5130210, DOI: 10.1111/1759-7714.12363.Peer-Reviewed Original ResearchConceptsProgression-free survivalResponse Evaluation CriteriaTumor cavitationPrognostic informationTreatment responseTumor responseTumor densitySignificant differencesPrediction of PFSRadiographic treatment responseAdditional prognostic informationUseful prognostic signCertain radiographic signsPrognostic signTumor diameterLung cancerShort-axis sizeRadiographic signsTumor assessmentPatientsSolid tumorsTumor changesRECIST1.1Imaging characteristicsPFS
2015
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas
Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLOS ONE 2015, 10: e0132134. PMID: 26132438, PMCID: PMC4488446, DOI: 10.1371/journal.pone.0132134.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Squamous CellCell MovementChemotherapy, AdjuvantCombined Modality TherapyCyclophosphamideDeoxycytidineDown-RegulationDoxorubicinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleGemcitabineGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLungLung NeoplasmsMaleMiddle AgedNeoplasm ProteinsNeoplasm StagingOrganoplatinum CompoundsPaclitaxelPneumonectomyPrognosisRNA InterferenceRNA, Small InterferingTranscription FactorsVinblastineVinorelbineConceptsLung squamous cell carcinomaSquamous cell carcinomaLung SCC patientsNon-small cell lung cancerLung SCC cellsLung SCC cell linesSCC patientsSCC cell linesAdjuvant chemotherapyCell carcinomaPredictive markerSCC cellsEMX2 expressionImproved overall survivalCurrent staging methodsTissue samplesCell lung cancerNovel prognostic markerAdjacent normal tissuesCell linesOverall survivalSurgical resectionLung cancerPatient outcomesPrognostic marker
2012
Laparoscopic vs Open Gastric Bypass Surgery: Differences in Patient Demographics, Safety, and Outcomes
Banka G, Woodard G, Hernandez-Boussard T, Morton JM. Laparoscopic vs Open Gastric Bypass Surgery: Differences in Patient Demographics, Safety, and Outcomes. JAMA Surgery 2012, 147: 550-556. PMID: 22786543, DOI: 10.1001/archsurg.2012.195.Peer-Reviewed Original ResearchConceptsLRYGB patientsGastric bypassMore complicationsOpen gastric bypass surgeryQuality Patient Safety IndicatorsRetrospective cohort studyGastric bypass surgeryHigh-volume hospitalsLonger median lengthNationwide Inpatient SamplePopulation-based studyLength of stayPatient safety indicatorsLower odds ratioHigher total chargesNumber of proceduresLRYGB cohortsNonroutine dispositionLaparoscopic RouxOpen RouxBypass surgeryPatient demographicsCohort studyComorbidity differencesMedian length
2011
Halo Effect for Bariatric Surgery: Collateral Weight Loss in Patients' Family Members
Woodard GA, Encarnacion B, Peraza J, Hernandez-Boussard T, Morton J. Halo Effect for Bariatric Surgery: Collateral Weight Loss in Patients' Family Members. JAMA Surgery 2011, 146: 1185-1190. PMID: 22006878, DOI: 10.1001/archsurg.2011.244.Peer-Reviewed Original ResearchConceptsGastric bypass surgeryBypass surgeryBody mass indexPatients' family membersAdult family membersHealthy behaviorsBariatric surgeryMass indexWeight lossLower body mass indexFamily membersMultidimensional health assessmentActivity levelsChildren of patientsSignificant weight lossDaily activity levelsQuality of lifeBariatric centerLifestyle counselingMorbid obesitySecondary outcomesWaist circumferenceObese childrenEffective treatmentUncontrollable eating
2010
Impaired Alcohol Metabolism after Gastric Bypass Surgery: A Case-Crossover Trial
Woodard GA, Downey J, Hernandez-Boussard T, Morton JM. Impaired Alcohol Metabolism after Gastric Bypass Surgery: A Case-Crossover Trial. Journal Of The American College Of Surgeons 2010, 212: 209-214. PMID: 21183366, DOI: 10.1016/j.jamcollsurg.2010.09.020.Peer-Reviewed Original ResearchConceptsGastric bypass surgeryBypass surgeryAlcohol metabolismBreath alcohol contentCase-crossover trialsGastric bypass patientsCase-crossover designEnduring treatmentRYGB patientsGastric bypassBariatric surgeryBypass patientsPreoperative levelsPublic health crisisSevere obesityPostoperative patientsPatientsDouble visionSurgeryDrinking habitsLess alcoholMonthsHealth crisisPoor psychological adjustmentIndustrialized worldOne Year Improvements in Cardiovascular Risk Factors: a Comparative Trial of Laparoscopic Roux-en-Y Gastric Bypass vs. Adjustable Gastric Banding
Woodard GA, Peraza J, Bravo S, Toplosky L, Hernandez-Boussard T, Morton JM. One Year Improvements in Cardiovascular Risk Factors: a Comparative Trial of Laparoscopic Roux-en-Y Gastric Bypass vs. Adjustable Gastric Banding. Obesity Surgery 2010, 20: 578-582. PMID: 20186576, DOI: 10.1007/s11695-010-0088-0.Peer-Reviewed Original ResearchConceptsBiochemical cardiovascular risk factorsLaparoscopic adjustable gastric bandingAdjustable gastric bandingCardiovascular risk factorsTotal cholesterolRisk factorsGastric bandingGastric bypassHs-CRPLipoprotein cholesterolExcess weightHigh-sensitivity C-reactive proteinLow-density lipoprotein cholesterolSensitivity C-reactive proteinHigh-density lipoprotein cholesterolBackgroundCoronary artery diseaseConsecutive bariatric patientsPreventable risk factorsY Gastric BypassC-reactive proteinSingle academic institutionCause of deathSignificant weight lossPost-op valuesSignificant improvement
2009
Probiotics Improve Outcomes After Roux-en-Y Gastric Bypass Surgery: A Prospective Randomized Trial
Woodard GA, Encarnacion B, Downey JR, Peraza J, Chong K, Hernandez-Boussard T, Morton JM. Probiotics Improve Outcomes After Roux-en-Y Gastric Bypass Surgery: A Prospective Randomized Trial. Journal Of Gastrointestinal Surgery 2009, 13: 1198-1204. PMID: 19381735, DOI: 10.1007/s11605-009-0891-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultBody Mass IndexConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGastric BypassHumansMaleMiddle AgedObesity, MorbidPatient SatisfactionPostoperative CarePostoperative ComplicationsProbabilityProbioticsProspective StudiesReference ValuesRisk AssessmentTreatment OutcomeWeight LossConceptsGastric bypass surgeryBacterial overgrowthProbiotic groupControl groupWeight lossBypass surgeryGreater percent excess weight lossPercent excess weight lossY Gastric Bypass SurgeryExcess weight lossProspective randomized trialsVitamin B12 levelsMethodsForty-four patientsQuality of lifeEnduring treatmentGastric bypassMorbid obesityB12 levelsPostoperative changesResultsAt 6Randomized trialsVitamin B12 availabilityProbiotic administrationGastrointestinal floraGI microbiota